Angitia Biopharmaceuticals Announces $120 Million Series C Financing
11. Dezember 2024 08:00 ET | Angitia Incorporated Limited
- Financing led by Bain Capital Life Sciences with significant participation from existing and new investors - Proceeds will support the development of AGA2118, AGA2115, AGA111 and other pipeline...
Angitia Biopharmaceuticals Announces Dosing of First Patient in Phase 2 Clinical Trial of AGA2118 for the Treatment of Osteoporosis
04. November 2024 07:30 ET | Angitia Incorporated Limited
WOODLAND HILLS, Calif., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Angitia Biopharmaceuticals, a clinical-stage biotechnology company focused on the discovery and development of innovative therapeutics for...
Angitia Biopharmaceuticals Presents First-in-Human Data on AGA2118 for Osteoporosis at ASBMR 2024
30. September 2024 07:30 ET | Angitia Incorporated Limited
WOODLAND HILLS, Calif., Sept. 30, 2024 (GLOBE NEWSWIRE) -- Angitia Biopharmaceuticals, a clinical-stage biotechnology company focused on the discovery and development of innovative therapeutics for...
Angitia Biopharmaceuticals to Present Data on AGA2118 for Osteoporosis at ASBMR 2024
16. September 2024 07:30 ET | Angitia Biopharmaceuticals
Angitia announces multiple presentations at ASBMR.